Update on precursor and early lesions of hepatocellular carcinomas

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 6, 2011, Pages 704-715

  Park, Young Nyun ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; DISEASE COURSE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PRECANCER;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958863399     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22(3):983-993.
2. Hytiroglou P, Park YN, Krinsky G, Theise ND. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am. 2007; 36(4): 867-887, vii. (Pubitemid 350051705)
3. Theise ND, Curado MP, Franceschi S, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Heise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010:205216.
4. Watanabe S, Okita K, Harada T, et al. Morphologic studies of the liver cell dysplasia. Cancer. 1983; 51(12):2197-2205. (Pubitemid 13106843)
5. Anthony PP, Vogel CL, Barker LF. Liver cell dysplasia: a premalignant condition. J Clin Pathol. 1973; 26(3):217-223.
6. Marchio A, Terris B, Meddeb M, et al. Chromosomal abnormalities in liver cell dysplasia detected by comparative genomic hybridisation. Mol Pathol. 2001; 54(4):270-274. (Pubitemid 32730405)
7. Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology. 2007; 45(4):968-976. (Pubitemid 46631565)
8. Nakanuma Y, Hirata K. Unusual hepatocellular lesions in primary biliary cirrhosis resembling but unrelated to hepatocellular neoplasms. Virchows Arch A Pathol Anat Histopathol. 1993; 422(1):17-23. (Pubitemid 23073660)
9. Zhao M, Zhang NX, Du ZY, Laissue JA, Zimmermann A. Three types of liver cell dysplasia (LCD) in small cirrhotic nodules are distinguishable by karyometry and PCNA labelling, and their features resemble distinct grades of hepatocellular carcinoma. Histol Histopathol. 1994; 9(1):73-83. (Pubitemid 24081002)
10. Makino Y, Shiraki K, Sugimoto K, et al. Histological features of cirrhosis with hepatitis C virus for prediction of hepatocellular carcinoma development; a prospective study. Anticancer Res. 2000; 20(5C):3709-3715. (Pubitemid 32002264)
11. Libbrecht L, Craninx M, Nevens F, Desmet V, Roskams T. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology. 2001; 39(1):66-73. (Pubitemid 32848276)
12. Borzio M, Bruno S, Roncalli M, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology. 1995; 108(3):812-817.
13. Ganne-Carrie N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis. Hepatology. 1996;23(5):1112-1118. (Pubitemid 26137055)
14. Koo JS, Kim H, Park BK, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol. 2008; 42(6):738-743.
15. Lee RG, Tsamandas AC, Demetris AJ. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology. 1997; 26(6):1415-1422. (Pubitemid 27520005)
16. Natarajan S, Theise ND, Thung SN, Antonio L, Paronetto F, Hytiroglou P. Large-cell change of hepatocytes in cirrhosis may represent a reaction to prolonged cholestasis. Am J Surg Pathol. 1997; 21(3):312-318.
17. Borzio M, Trere D, Borzio F, et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Pathol. 1998; 51(2):96-101. (Pubitemid 28261248)
18. Roncalli M, Borzio M, Brando B, Colloredo G, Servida E. Abnormal DNA content in liver-cell dysplasia: a flow cytometric study. Int J Cancer. 1989; 44(2): 204-207.
19. Thomas RM, Berman JJ, Yetter RA, Moore GW, Hutchins GM. Liver cell dysplasia: a DNA aneuploid lesion with distinct morphologic features. Hum Pathol. 1992; 23(5):496-503.
20. El-Sayed SS, El-Sadany M, Tabll AA, Soltan A, El-Dosoky I, Attallah AM. DNA ploidy and liver cell dysplasia in liver biopsies from patients with liver cirrhosis. Can J Gastroenterol. 2004; 18(2):87-91. (Pubitemid 38418033)
21. Terris B, lngster O, Rubbia L, et al. Interphase cytogenetic analysis reveals numerical chromosome aberrations in large liver cell dysplasia. J Hepatol. 1997; 27(2):313-319.
22. Zondervan PE, Wink J, Alers JC, et al. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol. 2000; 192(2):207-215.
23. Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hepatology. 1998; 28(4):953-958. (Pubitemid 28450255)
24. Kim H, Oh BK, Roncalli M, et al. Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology. 2009; 50(3):752-762.
25. Park YN, Roncalli M. Large liver cell dysplasia: a controversial entity. / Hepatol. 2006; 45(5):734-743. (Pubitemid 44466669)
26. Deugnier YM, Charalambous P, Le Quilleuc D, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology. 1993; 18(6):1363-1369. (Pubitemid 23348423)
27. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009; 49(2):658-664.
28. Kojiro M. Pathology of Hepatocellular Carcinoma. Maiden, MA: Blackwell Publishing; 2006:31-49.
29. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, Theise ND. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol. 1998; 22(6):656-662. (Pubitemid 28280267)
30. Roncalli M, Roz E, Coggi G, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology. 1999; 30(5):1174-1178. (Pubitemid 29510855)
31. Ueda K, Terada T, Nakanuma Y, Matsui O. Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a morphometric study. Hum Pathol. 1992;23(6):619-626.
32. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med. 2000; 124(7):1061-1065. (Pubitemid 30602050)
33. Theise ND, Park YN, Kojiro M. Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis. 2002; 6(2):497-512. (Pubitemid 34755902)
34. Terada T, Terasaki S, Nakanuma Y. A clinicopathologic study of adenomatous hyperplasia of the liver in 209 consecutive cirrhotic livers examined by autopsy. Cancer. 1993; 72(5):1551-1556. (Pubitemid 23249278)
35. Furuya K, Nakamura M, Yamamoto Y, Togei K, Otsuka H. Macroregenerative nodule of the liver: a clinicopathologic study of 345 autopsy cases of chronic liver disease. Cancer. 1988; 61(1):99-105. (Pubitemid 18023117)
36. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol. 1991; 22(2):172-178.
37. Theise ND, Schwartz M, Miller C, Thung SN. Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver expiants with cirrhosis. Hepatology. 1992; 16(4):949-955.
38. Borzio M, Fargion S, Borzio F, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol. 2003; 39(2):208-214. (Pubitemid 36920556)
39. Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer. 2006; 106(3):636-647. (Pubitemid 43157628)
40. Terasaki S, Kaneko S, Kobayashi K, Nonomura A, Nakanuma Y. Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenterology. 1998,115(5): 1216-1222. (Pubitemid 28485613)
41. Maggioni M, Coggi G, Cassani B, et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies. Hepatology. 2000; 32(5):942-946.
42. Sun M, Eshleman JR, Ferrell LD, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology. 2001; 33(6):1415-1424. (Pubitemid 32496978)
43. Tornillo L, Carafa V, Sauter G, et al. Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: high-grade dysplastic nodules represent early stages of hepatocellular carcinoma. Lab Invest. 2002; 82(5):547-553. (Pubitemid 34522367)
44. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int. 2008,28(2): 160-174. (Pubitemid 351201031)
45. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology. 2000; 32(5):970-979.
46. Oh BK, Chae KJ, Park C, et al. Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis. J Hepatol. 2003; 39(5):786-792. (Pubitemid 37372189)
47. Oh BK, Kim YJ, Park YN, Choi KJ, Kim KS, Park C. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis. Am J Gastroenterol. 2006; 101(4):831-838.
48. Oh BK, Kim YJ, Park C, Park YN. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol. 2005; 166(1):73-80. (Pubitemid 40051661)
49. Lee YH, Oh BK, Yoo JE, et al. Chromosomal instability, telomere shortening, and inactivation of p21(WAF1/CIP1) in dysplastic nodules of hepatitis B virus-associated multistep hepatocarcinogenesis. Mod Pathol. 2009; 22(8): 1121-1131.
50. Park YN, Kojiro M, Di Tommaso L, et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer. 2007; 109(5):915-923. (Pubitemid 46333533)
51. Nakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology. 1995; 22(1):101105.
52. Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis. 1999; 19(3):287-296. (Pubitemid 29488771)
53. Roncalli M, Park YN, Di Tommaso L. Histopathological classification of hepatocellular carcinoma. Dig Liver Dis. 2010; 42(suppl 3):S228-S234.
54. Kondo F, Kondo Y, Nagato Y, Tomizawa M, Wada K. Interstitial tumour cell invasion in small hepatocellular carcinoma: evaluation in microscopic and low magnification views. J Gastroenterol Hepatol. 1994; 9(6):604-612. (Pubitemid 24364612)
55. Nakashima Y, Nakashima O, Hsia CC, Kojiro M, Tabor E. Vascularization of small hepatocellular carcinomas: correlation with differentiation. Liver. 1999; 19(1):12-18. (Pubitemid 29034105)
56. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 125(11:89-97.
57. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer. 2003; 103(4):455-465. (Pubitemid 36020219)
58. Moriguchi H, Sato C. The values and limitations of glypican-3 as a novel tumor marker for hepatocellular carcinoma from clinical and economic view points. Gastroenterology. 2004; 127(2):679-680.
59. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007; 111(5):316-322.
60. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007; 45(3):725-734. (Pubitemid 46450624)
61. Abdul-Al HM, Makhlouf HR, Wang G, Goodman ZD. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008; 39(2):209-212.
62. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004; 10(19):66126621.
63. Garrido C, Gurbuxani S, Ravagnan L, Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun. 2001; 286(3):433-442. (Pubitemid 32912965)
64. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst. 2000,92(19):15641572.
65. Chuma M, Sakamoto M, Yamazaki K, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003,37(1) :198-207. (Pubitemid 36042161)
66. Christa L, Simon MT, Flinois JP, Gebhardt R, Brechot C, Lasserre C. Overexpression of glutamine synthetase in human primary liver cancer. Gastroenterology. 1994; 106(5):1312-1320. (Pubitemid 24129249)
67. Zucman-Rossi J, Benhamouche S, Godard C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. 2007; 26(5):774-780. (Pubitemid 46204256)
68. Osada T, Sakamoto M, Nagawa H, et al. Acquisition of glutamine synthetase expression in human hepatocarcinogenesis: relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis. Cancer. 1999; 85(4):819-831. (Pubitemid 29077558)
69. Moorman AF, de Boer PA, Geerts WJ, van den Zande L, Lamers WH, Charles R. Complementary distribution of carbamoylphosphate synthetase (ammonia) and glutamine synthetase in rat liver acinus is regulated at a pretranslational level. J Histochem Cytochem. 1988; 36(7):751-755.
70. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007; 46(3):740-748. (Pubitemid 47436120)
71. Park YN, Chae KJ, Kim YB, Park C, Theise N. Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer. 2001; 92(11):2733-2738. (Pubitemid 33091908)
72. Theise ND, Fiel IM, Hytiroglou P, et al. Macroregenerative nodules in cirrhosis are not associated with elevated serum or stainable tissue alphafetoprotein. Liver. 1995; 15(1):30-34.
73. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42:1208-1236. (Pubitemid 43112690)
74. Di Tommaso L, Destro A, Seok JY, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol. 2009; 50:746-754.